Published online Jun 25, 2024. doi: 10.5501/wjv.v13.i2.90951
Revised: March 2, 2024
Accepted: April 7, 2024
Published online: June 25, 2024
Processing time: 188 Days and 23.7 Hours
Hepatitis E virus (HEV) infection is now endemic worldwide. Most patients with acute infection recover uneventfully. Outbreaks and sporadic cases, particularly in high-risk individuals are emerging increasingly. The patients with risk factors like pregnancy and pre-existing chronic liver disease, present with or progress rapidly to severe disease. Immuno-suppression in post-transplant patients is an additional risk factor. Standardized FDA-approved diagnostic tests are the need of the hour. Further studies are needed to establish guideline-based treatment regimen and outbreak preparedness for HEV to decrease global morbidity, mortality, and healthcare burden. Policies for screening donors and transplant cases are requi
Core Tip: In this editorial we have tried to throw light on various aspects of hepatitis E virus, that help in better understanding about the virus, disease process, various diagnostic approaches, treatment and prevention. We are sure that this will be helpful to plan proper surveillance and management protocols with improved outcomes.
